Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia

Alexander M. Labeit, MDPhD, Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath, Leanne M. Cork, BSc (Hons), Corinne A. Hedgley, BSc (Hons), Letizia Foroni, MDPhDFRCPath, Wendy L. Osborne, MBBS (Hons) MRCP FRCPath, Gemma Gills, MSc BSc (Hons), Jane F. Apperley, MD, Tessa L. Holyoake, MDPhD, Ruth V. Bescoby, MSc BSc, Christopher Pocock, Thomas Zwingers, MSc, Philippa Burnell, Jenny L. Byrne, PhD, John H. McCullough, John M. Goldman, DM FRCP FRCPath, Richard E. Clark, MD, Stephen G. O'Brien, BSc (Hons) PhD MBChB FRCP MRCPath

Blood (2015) 126 (23): 4024.

https://doi.org/10.1182/blood.V126.23.4024.4024

Published: 2015

Journal Articles

Efficacy of Tyrosine Kinase Inhibitors (TKIs) as Third Line Therapy In Patients with Chronic Myeloid Leukaemia In Chronic Phase Who Have Failed Two Prior TKIs

Amr R Ibrahim, Marco Bua, Jamshid S Khorshad, Dragana Milojkovic, Lina Eliasson, Richard Szydlo, Letizia Foroni, MD, PhD, Alistair Reid, Hugues de Lavallade, Katayoun Rezvani, MD, PhD, John M. Goldman, DM, FRCP, FRCPath, FMedSci, Jane Apperley, MBChB, FRCP, FRCPath, David Marin, MD, FRCP

Blood (2010) 116 (21): 2274.

https://doi.org/10.1182/blood.V116.21.2274.2274

Published: 2010

Journal Articles

Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy.

Amr R Ibrahim, Dragana Milojkovic, Marco Bua, Jamshid S Khorshad, Richard Szydlo, Lina Eliasson, Letizia Foroni, MD, PhD, Alistair Reid, Hugues de Lavallade, Katayoun Rezvani, MD, PhD, John M. Goldman, DM, FRCP, FRCPath, FMedSci, Jane Apperley, MBChB, FRCP, FRCPath, David Marin, MD, FRCP

Blood (2010) 116 (21): 3414.

https://doi.org/10.1182/blood.V116.21.3414.3414

Published: 2010

Journal Articles

2009 Pandemic Influenza A H1N1 Vaccination In the Patients with Hematologic Malignancies: Requirement for Repeated Dosing to Optimize Seroprotection

Blood (2010) 116 (21): 677.

https://doi.org/10.1182/blood.V116.21.677.677

Published: 2010

Journal Articles

KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib

Ian H Gabriel, MD, David Marin, MD, FRCP, Shahzad Ahmad, Mr, Letizia Foroni, Hugues de Lavallade, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Stephen O'Brien, PhD, Ruhena Sergeant, Dragana Milojkovic, MD, Marco Bua, Abdullah Alsuliman, Ahmad Khoder, Dr, Kate Stringaris, MD, MRCP, FRCPath, Nichola Cooper, MD, John M. Goldman, DM, FRCP, FRCPath, FMedSci, Jane F. Apperley, Katayoun Rezvani, MD, PhD

Blood (2010) 116 (21): 888.

https://doi.org/10.1182/blood.V116.21.888.888

Published: 2010

Journal Articles

Long-Term Survival and Late Relapse in 5-Year Survivors of Allogeneic Hematopoietic-Cell Transplantation (HCT) for Chronic Myeloid Leukemia (CML) in First Chronic Phase.

John M. Goldman, DM, FRCP, FRCPath, Navneet S. Majhail, MD, MS, John P. Klein, PhD, Zhiwei Wang, MS, Kathleen A. Sobocinski, MS, Mukta Arora, MD, Mary M. Horowitz, MD, MS, J. Douglas Rizzo, MD, MS

Blood (2009) 114 (22): 3321.

https://doi.org/10.1182/blood.V114.22.3321.3321

Published: 2009

Journal Articles

Common Submicroscopic Genomic Imbalances Accompany the Ph Chromosome at Diagnosis in Chronic Myeloid Leukemia

Jamshid S Khorashad, MD, Valeria A De Melo, Heike Fiegler, PhD, Gareth Gerrard, PhD, Dan Brudzevsky, PhD, David Marin, MD, Jane F. Apperley, MBChB, FRCP, FRCPath, John M Goldman, DM, FRCP, FRCPath, Letizia Foroni, MD, PhD, FRCPath, Alistair G Reid, PhD

Blood (2008) 112 (11): 3113.

https://doi.org/10.1182/blood.V112.11.3113.3113

Published: 2008

NARROW

Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia

Efficacy of Tyrosine Kinase Inhibitors (TKIs) as Third Line Therapy In Patients with Chronic Myeloid Leukaemia In Chronic Phase Who Have Failed Two Prior TKIs

Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy.

2009 Pandemic Influenza A H1N1 Vaccination In the Patients with Hematologic Malignancies: Requirement for Repeated Dosing to Optimize Seroprotection

KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib

Long-Term Survival and Late Relapse in 5-Year Survivors of Allogeneic Hematopoietic-Cell Transplantation (HCT) for Chronic Myeloid Leukemia (CML) in First Chronic Phase.

Common Submicroscopic Genomic Imbalances Accompany the Ph Chromosome at Diagnosis in Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia

Efficacy of Tyrosine Kinase Inhibitors (TKIs) as Third Line Therapy In Patients with Chronic Myeloid Leukaemia In Chronic Phase Who Have Failed Two Prior TKIs

Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy.

2009 Pandemic Influenza A H1N1 Vaccination In the Patients with Hematologic Malignancies: Requirement for Repeated Dosing to Optimize Seroprotection

KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib

Long-Term Survival and Late Relapse in 5-Year Survivors of Allogeneic Hematopoietic-Cell Transplantation (HCT) for Chronic Myeloid Leukemia (CML) in First Chronic Phase.

Common Submicroscopic Genomic Imbalances Accompany the Ph Chromosome at Diagnosis in Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only